1 published article · Updated continuously
12 trials tracked for Scalp psoriasis: 9 in phase 3 or 4 and 3 with published results. The most-cited published study has 14 citations.
Showing the 12 most-cited and recently-updated of 12 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Risankizumab demonstrated significant efficacy for scalp psoriasis, with 60.8% of participants achieving a Scalp Investigator Global Assessment (IGA) of 0 or 1 at Week 16 (p<0.0001) 1. Roflumilast Foam 0.3% also showed statistically significant improvements, including a 66.4% success rate in Scalp Investigator Global Assessment (S-IGA) at Week 8 (p<0.0001) and significant improvement in the Scalp Itch-Numeric Rating Score (SI-NRS) at Week 2 (p=0.0005) 3.
Clobetasol propionate was evaluated in multiple formulations; a spray formulation showed clinical activity in reducing scaling, erythema, and plaque elevation by Week 4 2, while a shampoo formulation was compared against other corticosteroids where 21.8% of subjects preferred the clobetasol propionate shampoo over comparators (p=0.0003) 9. Xamiol gel demonstrated a success rate (Total Sign Score ≤1) of 64.2% at Week 4 8.
The topical suspension/gel LEO 80185 showed a 54.8% rate of controlled disease (Clear or Almost Clear) by Week 4, with low rates of adverse drug reactions ranging from 3.2% to 6.4% [11, 12]. Other interventions such as DSXS topical and DSXS did not show statistically significant differences in clinical success compared to their respective controls across various severity levels [6, 7].
AI synthesis of 5 cited trials, updated Jul 25, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
